These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10791121)

  • 1. Homocysteine in renal disease.
    Ducloux D; Motte G; Chalopin JM
    Clin Lab; 2000; 46(3-4):141-51. PubMed ID: 10791121
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic kidney disease: a risk factor for cardiovascular disease.
    Wali RK; Henrich WL
    Cardiol Clin; 2005 Aug; 23(3):343-62. PubMed ID: 16084283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiorenal interactions: clinical implication and role in pathogenesis of cardiovascular and renal diseases].
    Mukhin NA; Moiseev VS; Kobalava ZhD; Moiseev SV; Fomin VV
    Ter Arkh; 2004; 76(6):39-46. PubMed ID: 15332575
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cardiovascular disease in patients with 4 and 5 stage chronic kidney disease. Patient in chronic dialysis].
    Goicoechea MA
    Nefrologia; 2004; 24 Suppl(6):142-60, 187-235. PubMed ID: 15696904
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid metabolism and causal pathways for cardiovascular disease in chronic kidney disease.
    van Heyningen C
    Curr Opin Lipidol; 2009 Oct; 20(5):440-1. PubMed ID: 19741339
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypertension and cardiovascular risk in chronic kidney disease patients.
    Luño J; Rodriguez-Iturbe B; Ayus JC
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S157-8. PubMed ID: 17130254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine and cardiovascular disease in renal disease.
    Austen SK; Coombes JS; Fassett RG
    Nephrology (Carlton); 2003 Dec; 8(6):285-95. PubMed ID: 15012699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine or renal impairment: which is the real cardiovascular risk factor?
    Potter K; Hankey GJ; Green DJ; Eikelboom JW; Arnolda LF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1158-64. PubMed ID: 18356552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein metabolism and lipid management in chronic kidney disease.
    Kwan BC; Kronenberg F; Beddhu S; Cheung AK
    J Am Soc Nephrol; 2007 Apr; 18(4):1246-61. PubMed ID: 17360943
    [No Abstract]   [Full Text] [Related]  

  • 11. Biochemical risk markers: a novel area for better prediction of renal risk?
    Stuveling EM; Bakker SJ; Hillege HL; de Jong PE; Gans RO; de Zeeuw D
    Nephrol Dial Transplant; 2005 Mar; 20(3):497-508. PubMed ID: 15735241
    [No Abstract]   [Full Text] [Related]  

  • 12. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk.
    Wanner C; Drechsler C; Krane V
    J Ren Nutr; 2007 Jan; 17(1):75-8. PubMed ID: 17198938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated homocysteine levels in patients with end-stage renal disease.
    Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
    Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboxane biosynthesis and metabolism in cardiovascular and renal disease.
    Patrono C; Patrignani P; Daví G
    J Lipid Mediat; 1993; 6(1-3):411-5. PubMed ID: 8357999
    [No Abstract]   [Full Text] [Related]  

  • 16. New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism.
    De Caterina R; Zampolli A; Madonna R; Fioretti P; Vanuzzo D
    Ital Heart J; 2004 Jun; 5 Suppl 6():19S-24S. PubMed ID: 15185912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk factors in progressive renal disease.
    Harris KP
    Clin Med (Lond); 2002; 2(3):191-4. PubMed ID: 12108465
    [No Abstract]   [Full Text] [Related]  

  • 18. Kidney disease and cardiovascular disease: implications of dyslipidemia.
    Keane WF; Lyle PA
    Cardiol Clin; 2005 Aug; 23(3):363-72. PubMed ID: 16084284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
    Krane V; Wanner C
    Am J Kidney Dis; 2005 Mar; 45(3):607-9. PubMed ID: 15754285
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cardiovascular, renal and other chronic diseases. Early intervention is necessary in chronic kidney disease].
    Martín de Francisco AL; Aguilera L; Fuster V
    Nefrologia; 2009; 29(1):6-9. PubMed ID: 19240765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.